Document ID: FDA-2018-D-4629-0001
Agency: fda
Document Type: Notice
Title: Survey Methodologies To Assess Risk Evaluation and Mitigation Strategies Goals That Relate to Knowledge; Draft Guidance for Industry; Availability
Posted Date: 2019-02-01T05:00Z

[Federal Register Volume 84, Number 22 (Friday, February 1, 2019)]
[Notices]
[Pages 1159-1161]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-00749]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-D-4629]

Survey Methodologies To Assess Risk Evaluation and Mitigation 
Strategies Goals That Relate to Knowledge; Draft Guidance for Industry; 
Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of a draft guidance for industry entitled ``Survey 
Methodologies to Assess REMS Goals That Relate to Knowledge; Draft 
Guidance For Industry.'' This draft guidance provides recommendations 
to industry on conducting risk evaluation and mitigation strategies 
(REMS) assessment surveys used to evaluate respondent knowledge of 
REMS-related information. Most applicants use surveys to evaluate 
patients' and healthcare providers' understanding of the serious risks 
associated with, and safe use of, their drugs to assess REMS knowledge 
goals. The draft guidance discusses general principles and 
recommendations related to conducting REMS assessment knowledge 
surveys, including study design, survey instrument development, survey 
data collection and processing, and data analysis.

DATES: Submit either electronic or written comments on the draft 
guidance by April 2, 2019 to ensure that the Agency considers your 
comment on this draft guidance before it begins work on the final 
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as 
follows:

[[Page 1160]]

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2018-D-4629 for the ``Survey Methodologies to Assess REMS Goals 
That Relate to Knowledge.'' Received comments will be placed in the 
docket and, except for those submitted as ``Confidential Submissions'' 
publicly viewable at https://www.regulations.gov or at the Dockets 
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to 
the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002, or to the 
Office of Communication, Outreach and Development, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send 
one self-addressed adhesive label to assist that office in processing 
your requests. See the SUPPLEMENTARY INFORMATION section for electronic 
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Brian Gordon, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 22, Rm. 2486, Silver Spring, MD 20993-0002, 301-
796-3960, Brian.Gordon@fda.hhs.gov; Doris Auth, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 22, Rm. 2480, Silver Spring, MD 20993-0002, 301-
796-0487, Doris.Auth@fda.hhs.gov; or Stephen Ripley, Center for 
Biologics Evaluation and Research, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 
240-402-7911.

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing the availability of a draft guidance for industry 
entitled ``Survey Methodologies to Assess REMS Goals That Relate to 
Knowledge.'' The Food and Drug Administration Amendments Act of 2007 
(FDAAA) created section 505-1 (21 U.S.C. 355-1) of the Federal Food, 
Drug, and Cosmetic Act (FD&C Act), which authorizes FDA to require a 
REMS for certain drugs if FDA determines that a REMS is necessary to 
ensure that the benefits of a drug outweigh its risks.
    REMS elements may include a medication guide, a patient package 
insert, and/or a communication plan. FDA may also require certain 
elements to assure safe use (ETASU) as part of a REMS. The ETASU can 
include, for example, requirements that health care providers who 
prescribe the drug have particular training or experience, that 
patients using the drug be monitored, or that the drug be dispensed to 
patients with evidence or other documentation of safe use conditions. 
Certain REMS with ETASU may also include an implementation system 
through which the sponsor is able to monitor and evaluate 
implementation of the ETASU and work to improve their implementation. 
All REMS for drugs approved under a new drug application or a biologics 
license application must include a timetable for submission of 
assessments of the REMS. The timetable for submission of assessments 
must be, at a minimum, an assessment by 18 months after the strategy is 
initially approved, an assessment by 3 years after the strategy is 
initially approved, and an assessment in the 7th year after the initial 
approval of the REMS. For additional information about REMS, see the 
draft guidance for industry ``Format and Content of a REMS Document,'' 
(82 FR 47529, October 12, 2017) available at https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm184128.pdf.
    The FD&C Act requires applicants to conduct assessments to evaluate 
the effectiveness of REMS. The statute specifies that the assessment 
for REMS must include an assessment of the extent to which the approved 
strategy,

[[Page 1161]]

including each element of the strategy, is meeting the goal or whether 
one or more such goals or such elements should be modified (section 
505-1(g)(3) of the FD&C Act). The statute does not specifically 
describe how this assessment should be conducted. Many REMS include a 
goal related to knowledge, such as to inform or educate patients and 
healthcare providers about the serious risks associated with and safe 
use of a drug. When knowledge goals are part of a REMS, the REMS 
assessment plan generally includes, as appropriate, an evaluation of 
patients' and healthcare providers' understanding of the serious 
risk(s) associated with, and safe use of, the drug.
    The purpose of the REMS knowledge assessment is to evaluate the 
target populations' knowledge about the serious risk(s) and safe use of 
the drug. Most applicants use surveys to evaluate patients' and 
healthcare providers' understanding of the serious risk(s) associated 
with, and safe use of, their drugs to assess REMS knowledge goals.
    This draft guidance, which describes best practices for the design, 
conduct, and data analyses of the results of REMS assessment knowledge 
surveys to evaluate patients' and healthcare providers' understanding 
of the serious risk(s) associated with, and safe use of, a drug, 
incorporates input obtained from the June 7, 2012, public workshop on 
``REMS Assessments: Social Science Methodologies to Assess Goals 
Related to Knowledge,'' and the comments submitted to the docket opened 
in association with the workshop (FDA-2012-N-0408).
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the Agency's current thinking on conducting 
risk evaluation and mitigation strategy assessment surveys used to 
assess respondent knowledge of REMS-related information. It does not 
establish any rights for any person and is not binding on FDA or the 
public. You can use an alternative approach if it satisfies the 
requirements of the applicable statutes and regulations. This guidance 
is not subject to Executive Order 12866.

II. Paperwork Reduction Act of 1995

    This guidance refers to collections of information that are subject 
to review by the Office of Management and Budget (OMB) under the 
Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). Elsewhere in 
this issue of the Federal Register, FDA is announcing the availability 
of the draft guidance ``REMS Assessment: Planning and Reporting.'' The 
assessment of burden hours included in the NOA for the draft guidance 
``REMS Assessment: Planning and Reporting'' includes the burden for 
conducting knowledge surveys when conducted in support of a REMS 
Assessment.

III. Electronic Access

    Persons with access to the internet may obtain the document at 
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, or 
https://www.regulations.gov.

    Dated: January 17, 2019.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2019-00749 Filed 1-31-19; 8:45 am]
BILLING CODE 4164-01-P